Abstract:Abstract Background High density lipoprotein (HDL) exerts various atheroprotective functions including cholesterol efflux capacity (CEC). HDL can attenuate lipid burden at atherosclerotic lesion by CEC. Based on the HDL`s role for moderate atherosclerosis, HDL-cholesterol level which indicates the amount of HDL has been evaluated to assess the risk of cardiovascular disease (CVD). Nevertheless, many clinical studies demonstrated that HDL-cholesterol level does not always reflect the risk of CVD, and CEC which represents the quality of HDL is considered as surrogate biomarker for CVD. CEC is prospective biomarker for CVD risk assessment, however, CEC measurement encounters barriers for clinical application because of its requirements of cultured cell and radioactive substance for conventional CEC assay. To overcome these problems, we invented a novel CEC assay called immobilized liposome-bound gel beads (ILG) method. This method is cell-free assay and utilizes a fluorescence substance as cholesterol tracer. Although the ILG method is useful assay for clinical application, previous study revealed that bilirubin caused false positive error on CEC value. Hence, current ILG method might produce incorrect CEC evaluation for patients with hyperbilirubinemia and even healthy subjects within the range of biological variation of bilirubin. In this study, we improved the influence of bilirubin for ILG method by using bilirubin oxidase (BOD). Methods BOD (Asahi Kasei Corp.) was added to 10 mM Tris-HCl (pH 7.4) containing 150 mM of NaCl and 1 mM of Na2EDTA (Buffer A). Bilirubin from ‘Interference check A Plus’ (Sysmex Inc.) was added to serum (free-: 10 mg/dL, conjugated-:9.7 mg/dL), and apoB-depleted serum (BDS) was derived from the bilirubin additive serum using polyethylene glycol. After the prepared bilirubin additive BDS was incubated with BOD-containing Buffer A for 16 h, the absorbance spectrum was analyzed. In addition, the time course of bilirubin decrement was monitored during 16 h-incubation. We further measured the fluorescence intensity of bilirubin additive BDS incubated with BOD-containing Buffer A. Using the newly developed BOD-containing Buffer A for ILG method, CEC of bilirubin additive serum was evaluated. Finally, we measured CEC of 4 healthy individuals by conventional and the improved ILG method. The CEC value was standardized by fluorescence intensity of reference sample which was measured in every assay. Results BOD contained in Buffer A could convert bilirubin to biliverdin from results of absorbance spectrum. According to the time course of bilirubin decrement, both free- and conjugated-bilirubin were oxidized to biliverdin in approximately 6 h. By converting bilirubin to biliverdin, fluorescence light was weakened greatly. We confirmed that there was no significant difference of CEC values between non bilirubin-additive serum and bilirubin additive serum. Compared healthy individual CEC values measured by conventional and improved ILG method, all subjects showed significant decrease of CEC values from the improved method, and false positive error caused by bilirubin was ameliorated. Conclusion In this study, we achieved to improve the positive error caused by bilirubin on CEC assay using ILG method. This improvement would contribute to more accurate CEC assessment by ILG method and advance the clinical application of this method.

Investigation on the Interference of Bilirubin and Hemoglobin for Different Urinary Albumin Measurements

Studies on the interference by haemoglobin in the determination of bilirubin

A-209 Application of Bilirubin Oxidase for Improvement of False Positive Error Caused by Bilirubin on Cholesterol Efflux Capacity Assay by Immobilize Liposome-Bound Gel Beads method

Measurement of the modification and interference rate of urinary albumin detected by size-exclusion HPLC

Performance evaluation of four detection systems for total bilirubin

Influence and Correction of Hemolysis on the Accuracy of Biochemical Tests

Clinical Significance of Urine Albumin and Current Progress in Measurement

Comparison of the results for three automated immunoassay systems in determining serum HBV markers.

Effects of hemolysis, bilirubin, and lipemia interference on coagulation tests detected by two analytical systems

Performance evaluation of nine commonly used urine albumin assay systems

Study on the Interaction Between Bilirubin and Human Serum Albumin by Fluorescence Spectroscopy

Paraprotein Interferences: Insights from a Short Study Involving Multiple Platforms and Multiple Measurands

Influence of Different Bilirubin Concentrations on Plasma PT and APTT Detection

Influence of Blood Samples Collection on the Results of Biochemical Detection in ICU Patients

Interference of Rare IgA Type M Protein on Clinical Chemistry Determination

The analysis of aminoglycoside interference in urine total protein determination

Synthesis and Characterization of Novel Adsorbents with Different Ligand Composition for Bilirubin Conjugated with Albumin

Detection of serum retinol-binding protein,pre-albumin and albumin in patients with hepatitis B cirrhosis

Influence of blood fat level on two methods for determination of hemoglobin and its correction

A Method for Compensating Hemoglobin Interference in Total Serum Bilirubin Measurement Using a Simple Two-Wavelength Reflectance Photometer

The Impact of Perioperative Bilirubin and Albumin Levels on Postoperative Early Complications in Adult Liver Transplantation